Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19470252 | 0.96 | FGFR1 (0.49) | FGFR1TLR7SLC22A6EP300 | |
| SCHEMBL19470297 | 0.89 | FGFR1 (0.53) | FGFR1TLR7SLC22A6 | |
| SCHEMBL19470470 | 0.88 | FGFR1 (0.57) | FGFR1SLC22A6CYP3A4CYP2D6EP300 | |
| SCHEMBL16039362 | 0.87 | FGFR1 (0.50) | FGFR1 | |
| SCHEMBL19470310 | 0.86 | FGFR1 (0.50) | FGFR1TLR7SLC22A6EP300 | |
| SCHEMBL19470494 | 0.86 | FGFR1 (0.59) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL19470531 | 0.84 | FGFR1 (0.53) | FGFR1SLC22A6EP300 | |
| SCHEMBL16037941 | 0.84 | FGFR1 (0.46) | FGFR1 | |
| SCHEMBL5802198 | 0.83 | FGFR1 (0.71) | FGFR1SLC22A6CYP3A4CYP2D6EP300 | |
| SCHEMBL19470481 | 0.83 | FGFR1 (0.55) | FGFR1SLC22A6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401320-B1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS FOR USE IN TREATING HUMAN PAPILLOMA VIRUS, CERVICAL INTRAEPITHELIAL NEOPLASIA, ANAL INTRAEPITHELIAL NEOPLASIA, OR VULVAR INTRAEPITHELIAL NEOPLASIA | UNIV CALIFORNIA (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3401320-A1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS FOR USE IN TREATING HUMAN PAPILLOMA VIRUS, CERVICAL INTRAEPITHELIAL NEOPLASIA, ANAL INTRAEPITHELIAL NEOPLASIA, OR VULVAR INTRAEPITHELIAL NEOPLASIA | The Regents of the University of California (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10076532-B2 | Acyclic nucleoside phosphonate diesters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-18 | — | — | US | disclosed |
| EP-2970346-B1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS | UNIV CALIFORNIA (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170304330-A1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076532-B2 | Acyclic nucleoside phosphonate diesters | NTPCR, PNP, TYMP | FGFR1 3394/4885TLR7 1698/4885SLC22A6 1764/4885 |
| US-20170304330-A1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS | NTPCR, PNP, TYMP | FGFR1 3394/4885TLR7 1698/4885SLC22A6 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.